# Boston HIV CTU

> **NIH NIH UM1** · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $4,358,930

## Abstract

The Boston/Jackson/Providence HIV Clinical Trials Unit (BJP HIV CTU) will conduct clinical trials to address
research priorities of three NIAID HIV/AIDS Clinical Trials Networks (CTNs): HIV therapeutics; integrated
strategies for HIV prevention; and HIV vaccines. The BJP HIV CTU brings together a collaborative group of
highly experienced investigators with decades of experience in HIV-related treatment, prevention and vaccine
research. The BJP HIV CTU comprises five existing Clinical Research Sites (CRSs): therapeutics CRSs at
Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital in Boston, MA and The Miriam
Hospital in Providence, RI; a vaccine CRS at BWH; and a combined prevention and vaccine CRS at Fenway
Health (also in Boston). Two new CRSs are proposed—a prevention CRS at University of Mississippi Medical
Center in Jackson, MS and a vaccine CRS at Beth Israel Deaconess Medical Center (BIDMC) in Boston. The
BJP HIV CTU and its component CRSs will function as an integrated, collaborative consortium to coordinate and
implement clinical trials designed by the Leadership Groups of the NIAID-funded HIV/AIDS CTNs. The five
existing CRSs have been extremely effective in conducting studies and contributing substantially to the scientific
agendas of their respective CTNs. Expansion of our existing CTU to include two new CRSs devoted to HIV
prevention and vaccine research, respectively, substantially enhances our capacity to conduct clinical trials
critical to developing more effective means of HIV prevention and testing candidate vaccines. The proposed
UMMC Prevention CRS is located in Jackson, MS a city in the southeastern United States with a predominantly
African American population that ranked 4th highest in HIV infection and 5th highest in the rate of AIDS diagnoses
among US metropolitan areas. The proposed Vaccine CRS within the Center for Virology and Vaccine Research
at BIDMC will engage investigators who have made major and sustained scientific contributions to the HIV
vaccine field over the past 15 years. The BJP HIV CTU will be led by three highly experienced PIs, Drs. Daniel
Kuritzkes, Kenneth Mayer and Lindsey Baden, and will include highly accomplished CRS leaders and
collaborating investigators. The CTU will function as an integrated, highly collaborative consortium that will have
centralized planning, resource allocation, decision-making and financial management through an efficient
administration plan. Centralized resources include a Clinical Research Laboratory, a Research Pharmacy
Coordinator, Data and Quality Management Plans and a Community Engagement Core. The CTU has diverse
and accessible populations for study, representing communities most affected by HIV. Each CRS has well-
grounded connections in the communities in which they are based. The BJP HIV CTU is well-poised to carry out
efficient high-quality clinical trials to address major questions in HIV clinical research. Its leadership and
administrative stru...

## Key facts

- **NIH application ID:** 10057052
- **Project number:** 2UM1AI069412-15
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Lindsey Robert Baden
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $4,358,930
- **Award type:** 2
- **Project period:** 2007-01-15 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10057052

## Citation

> US National Institutes of Health, RePORTER application 10057052, Boston HIV CTU (2UM1AI069412-15). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10057052. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*